ResMed (RMD) Reports In-Line Q3 EPS, Miss on Revenues
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $221.97 --0%
Revenue Growth %: +6.9%
Financial Fact:
Diluted weighted average shares outstanding: 142.09M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +6.9%
Financial Fact:
Diluted weighted average shares outstanding: 142.09M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q3 EPS of $0.71, in-line with the analyst estimate of $0.71. Revenue for the quarter came in at $514.2 million versus the consensus estimate of $519.87 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Top Wealth Group expects net profit to double in fiscal 2026
- TD Cowen on Alaska Air (ALK): 'Can Alaska ReAccelerate?'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
